Ongoing Studies for Patients with Relapsed/Refractory AML

Video

Daniel J. DeAngelo, MD, PhD, associate professor of medicine at Harvard Medical School, and a member of the Adult Leukemia Program at the Dana-Farber Cancer Institute, discusses some of the clinical trials currently ongoing for patients with relapsed/refractory acute myeloid leukemia (AML). DeAngelo says he primarily uses targeted and combination therapies.

Related Videos
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
John Mascarenhas, MD, an expert on myelofibrosis
Related Content